CCND1 and breast carcinoma: Panobinostat accelerated the expression of APCL and blocked Wnt/β-catenin pathway via promotion of β-catenin degradation in breast cancer, resulting in inactivation of β-catenin targets, including c-Myc, CD44, Cyclin D1 and c-Jun, which contributed to inhibition of tumor growth and metastasis (76).